Bile Salt Receptor TGR5 is Highly Expressed in Esophageal Adenocarcinoma and Precancerous Lesions with Significantly Worse Overall Survival and Gender Differences

Overview

Journal Clin Exp Gastroenterol

Publisher Dove Medical Press

Specialty Gastroenterology

Date 2017 Feb 23

PMID 28223834

Citations 10

Authors

Chunhong Pang

Amy Lalonde

Tony E Godfrey

Jianwen Que

Jun Sun

Tong Tong Wu

Zhongren Zhou

Affiliations

Soon will be listed here.

Abstract

Bile acid reflux in the esophagus plays an important role in the carcinogenesis of esophageal adenocarcinoma (EAC). The G-protein coupled bile acid receptor (TGR5) has been associated with the development of gastrointestinal cancer. However, little is known regarding the role of TGR5 in esophageal carcinoma and precancerous lesions. We analyzed genomic DNA from 116 EACs for copy number aberrations via Affymetrix SNP6.0 microarrays. The gene locus was amplified in 12.7% (14/116) of the EACs. The TGR5 protein expression was also assessed using immunohistochemistry from tissue microarrays, including Barrett's esophagus (BE), low-(LGD) and high-grade dysplasia (HGD), columnar cell metaplasia (CM), squamous epithelium (SE), EAC and squamous cell carcinoma. The TGR5 protein was highly expressed in 71% of EAC (75/106), 100% of HGD (11/11), 72% of LGD (13/18), 66% of BE (23/35), 84% of CM (52/62), and 36% of SE (30/83). The patients with high expression of TGR5 exhibited significantly worse overall survival compared to the patients with nonhigh expression. TGR5 high expression was significantly increased in the males compared to the females in all cases with an odds ratio of 1.9 times. The vitamin D receptor (VDR) was significantly correlated with TGR5 expression. Our findings indicated that TGR5 may play an important role in the development and prognosis of EAC through a bile acid ligand. Gender differences in TGR5 and VDR expression may explain why males have a higher incidence of EAC compared to females.

Citing Articles

Bile Acids and Microbiota Interplay in Pancreatic Cancer.

Malhotra P, Palanisamy R, Caparros-Martin J, Falasca M Cancers (Basel). 2023; 15(14).

PMID: 37509236 PMC: 10377396. DOI: 10.3390/cancers15143573.

Inflammatory and Proliferative Pathway Activation in Human Esophageal Myofibroblasts Treated with Acidic Bile Salts.

Patankar M, Li M, Khalatbari A, Castle J, Hu L, Zhang C Int J Mol Sci. 2022; 23(18).

PMID: 36142285 PMC: 9498994. DOI: 10.3390/ijms231810371.

The role of bile acids in carcinogenesis.

Rezen T, Rozman D, Kovacs T, Kovacs P, Sipos A, Bai P Cell Mol Life Sci. 2022; 79(5):243.

PMID: 35429253 PMC: 9013344. DOI: 10.1007/s00018-022-04278-2.

Bile reflux and hypopharyngeal cancer (Review).

Vageli D, Doukas S, Doukas P, Judson B Oncol Rep. 2021; 46(5).

PMID: 34558652 PMC: 8485019. DOI: 10.3892/or.2021.8195.

Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome.

Portincasa P, Di Ciaula A, Garruti G, Vacca M, De Angelis M, Wang D Nutrients. 2020; 12(12).

PMID: 33266235 PMC: 7760347. DOI: 10.3390/nu12123709.

References

Nagathihalli N, Beesetty Y, Lee W, Washington M, Chen X, Lockhart A . Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids. Cancer Res. 2014; 74(7):2062-72. PMC: 3975694. DOI: 10.1158/0008-5472.CAN-13-2329. View

Campbell F, Xu H, El-Tanani M, Crowe P, Bingham V . The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol. 2009; 79(1):1-9. PMC: 2824849. DOI: 10.1016/j.bcp.2009.09.005. View

Fang Y, Chen X, Bajpai M, Verma A, Das K, Souza R . Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma. Ann N Y Acad Sci. 2013; 1300:187-199. DOI: 10.1111/nyas.12249. View

Corley D, Kubo A, Levin T, Block G, Habel L, Rumore G . Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut. 2008; 58(2):182-8. PMC: 2671084. DOI: 10.1136/gut.2008.163360. View

Cao W, Tian W, Hong J, Li D, Tavares R, Noble L . Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Physiol Gastrointest Liver Physiol. 2012; 304(4):G322-7. PMC: 3566614. DOI: 10.1152/ajpgi.00263.2012. View

Chen X, Yang C . Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis. 2001; 22(8):1119-29. DOI: 10.1093/carcin/22.8.1119. View

Houten S, Watanabe M, Auwerx J . Endocrine functions of bile acids. EMBO J. 2006; 25(7):1419-25. PMC: 1440314. DOI: 10.1038/sj.emboj.7601049. View

Zhou Z, Bandla S, Ye J, Xia Y, Que J, Luketich J . Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies. BMC Gastroenterol. 2014; 14:78. PMC: 3998234. DOI: 10.1186/1471-230X-14-78. View

Hu Y, Jones C, Gellersen O, Williams V, Watson T, Peters J . Pathogenesis of Barrett esophagus: deoxycholic acid up-regulates goblet-specific gene MUC2 in concert with CDX2 in human esophageal cells. Arch Surg. 2007; 142(6):540-4. DOI: 10.1001/archsurg.142.6.540. View

10.

Matsuzaki J, Suzuki H, Tsugawa H, Watanabe M, Hossain S, Arai E . Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. Gastroenterology. 2013; 145(6):1300-11. DOI: 10.1053/j.gastro.2013.08.008. View

11.

Guo C, Su J, Li Z, Xiao R, Wen J, Li Y . The G-protein-coupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway. Oncotarget. 2015; 6(33):34402-13. PMC: 4741461. DOI: 10.18632/oncotarget.5353. View

12.

Chang C, Mulholland H, Cantwell M, Anderson L, Johnston B, McKnight A . Vitamin d receptor gene variants and esophageal adenocarcinoma risk: a population-based case-control study. J Gastrointest Cancer. 2011; 43(3):512-7. DOI: 10.1007/s12029-011-9322-9. View

13.

Raimondi S, Johansson H, Maisonneuve P, Gandini S . Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009; 30(7):1170-80. DOI: 10.1093/carcin/bgp103. View

14.

Hu Y, Bandla S, Godfrey T, Tan D, Luketich J, Pennathur A . HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol. 2011; 24(7):899-907. PMC: 3138485. DOI: 10.1038/modpathol.2011.47. View

15.

Hong J, Behar J, Wands J, Resnick M, Wang L, DeLellis R . Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut. 2009; 59(2):170-80. PMC: 3049934. DOI: 10.1136/gut.2009.188375. View

16.

Trowbridge R, Mittal S, Sharma P, Hunter W, Agrawal D . Vitamin D receptor expression in the mucosal tissue at the gastroesophageal junction. Exp Mol Pathol. 2012; 93(2):246-9. PMC: 3411275. DOI: 10.1016/j.yexmp.2012.05.007. View

17.

Tamagawa Y, Ishimura N, Uno G, Yuki T, Kazumori H, Ishihara S . Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus. Lab Invest. 2012; 92(6):896-909. DOI: 10.1038/labinvest.2012.56. View

18.

Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H, Yoshiba M . Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun. 2007; 354(1):154-9. DOI: 10.1016/j.bbrc.2006.12.168. View

19.

Trowbridge R, Sharma P, Hunter W, Agrawal D . Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma. Exp Mol Pathol. 2012; 93(1):147-53. PMC: 3400680. DOI: 10.1016/j.yexmp.2012.04.018. View

20.

De Gottardi A, Dumonceau J, Bruttin F, Vonlaufen A, Morard I, Spahr L . Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol Cancer. 2006; 5:48. PMC: 1624849. DOI: 10.1186/1476-4598-5-48. View